DermatologistsBlog.com Interview with:
Dr. Ahmad Tarhini, MD, PhD
Associate Professor of Medicine, Clinical and Translational Science
Department of Medicine
Division of Hematology/Oncology
University of Pittsburgh
DermatologistsBlog.com: What are the main findings of the study?
Dr. Tarhini: In evaluating the patients’ tumors at baseline (before initiating treatment with ipilimumab), we found that the differential expression of a relatively small group of genes that can be characterized as being immune related can significantly distinguish patients who benefited from ipilimumab immunotherapy versus those who did not.
Read the full post »